Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Scientific Reports|August 5, 2020
Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk scoreShun Kaneko, Masayuki Kurosaki, Kouji Joko, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 12, 2026
Effect of Direct-Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in JapanHironori Ochi, Masayuki Kurosaki, Takaaki Tanaka, et al.
Cancer Research|April 1, 2022
Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field CancerizationKen Kumagai, Takahiro Shimizu, Atsushi Takai, et al.
Journal of Gastroenterology and Hepatology|April 27, 2025
Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus Untreated Low-Level Viremia in HBV-Compensated CirrhosisNobuharu Tamaki, Daniel Q Huang, Hyung Woong Lee, et al.
Nature Communications|December 5, 2013
MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in miceTakahiro Horie, Tomohiro Nishino, Osamu Baba, et al.
Cancer Immunology, Immunotherapy : CII|August 4, 2022
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumabTatsuki Ikoma, Mototsugu Shimokawa, Toshihiko Matsumoto, et al.
Hepatology (Baltimore, Md.)|January 12, 2023
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosisDaniel Q Huang, Nobuharu Tamaki, Hyung Woong Lee, et al.
Hepatology Communications|October 22, 2021
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C VirusNobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, et al.
Pageof 15